Advanced Medical Solutions Group (AIM:AMS) expects to report half-year revenue of approximately £115.2 million for the six months ended 30 June, up from £110.8 million a year earlier.
The AIM-listed tissue-healing medical device company said some first-half orders shipped later than planned, slipping into early July.
Progress expanding direct sales in Europe has also led to some destocking among distributors, weighing on sales in the period.
The group's Advance Closure division was also lapping a strong comparator from the first half of 2025, when order phasing from a key strategic partner boosted results, a factor flagged in its preliminary results on 18 March.
The integration of Peters Surgical and Syntacoll remains on track.
The board said it remains confident of delivering full-year 2026 EBITDA in line with current market expectations.
"With our strengthened portfolio, and a pipeline of exciting and significant opportunities, we remain confident in the future prospects of the Group and delivering sustained long-term value", said chief executive Chris Meredith.
News Intelligence what this means for the company
Advanced Medical Solutions reported H1 2026 revenue of £115.2m, up 3.9% year-on-year, but acknowledged that order timing delays and European distributor destocking weighed on the period. The company reaffirmed full-year EBITDA guidance despite these headwinds, signalling management confidence that near-term operational friction will not derail 2026 targets. This matters because AMS is mid-acquisition by H.B. Fuller (targeted end-2026), and maintaining guidance visibility reduces deal-completion risk.
The revenue beat modest growth expectations and the EBITDA reaffirmation is reassuring, but the disclosure of order delays and distributor destocking suggests execution challenges in the near term. For shareholders, the key variable remains regulatory clearance and deal completion by end-2026; operational momentum is secondary to that gate.
Insights assembled by AI. Editor-reviewed and grounded in tickstock’s coverage and proprietary knowledge graph.
Content is for informational purposes only, not financial advice.
